A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (6) , 1789-1793
- https://doi.org/10.1158/1078-0432.ccr-06-2270
Abstract
Purpose: To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG).Keywords
This publication has 15 references indexed in Scilit:
- HSP90 and the chaperoning of cancerNature Reviews Cancer, 2005
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid TumorsJournal of Clinical Oncology, 2005
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special ImperativesJournal of Clinical Oncology, 2004
- Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERKPublished by Elsevier ,2003
- Geldanamycin decreases Raf‐1 and Akt levels and induces apoptosis in neuroblastomasInternational Journal of Cancer, 2002
- HSP90 as a new therapeutic target for cancer therapy: the story unfoldsExpert Opinion on Biological Therapy, 2002
- Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperoneOncogene, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000